Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs

Amino Acids

Volumn 49, Issue 9, 2017, Pages 1535-1541

  Deluyker, Dorien ^a   Evens, Lize ^a   Bito, Virginie ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

Advanced glycation end products; Cardiovascular dysfunction; High molecular weight advanced glycation end products; Low molecular weight advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; SCLEROPROTEIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM; CONTRACTILE PROTEIN; PROTEIN BINDING;

BIOAVAILABILITY; CARDIOVASCULAR DISEASE; DIABETIC CARDIOMYOPATHY; ELASTICITY; HEART PROTECTION; HUMAN; LIPID PEROXIDATION; MOLECULAR WEIGHT; MUSCLE RIGIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; TISSUE DISTRIBUTION; UPREGULATION; CARDIAC MUSCLE; CELL AGING; CHEMISTRY; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY;

CALCIUM; CARDIOVASCULAR DISEASES; CELLULAR SENESCENCE; CONTRACTILE PROTEINS; GENE EXPRESSION REGULATION; GLYCATION END PRODUCTS, ADVANCED; HUMANS; MOLECULAR WEIGHT; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN BINDING; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS;

EID: 85023771989     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-017-2464-8     Document Type: Review

References (78)

1. Acharya AS, Manning JM (1983) Reaction of glycolaldehyde with proteins: latent crosslinking potential of alpha-hydroxyaldehydes. Proc Natl Acad Sci USA 80(12):3590–3594
2. Ahmed N (2005) Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Res Clin Pract 67(1):3–21
3. Ahmed N, Thornalley PJ (2007) Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9(3):233–245
4. Ahmed N, Babaei-Jadidi R et al (2005) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48(8):1590–1603
5. Aleshin A, Ananthakrishnan R et al (2008) RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol 294(4):H1823–H1832
6. Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21(1):3–12
7. Berg TJ, Snorgaard O et al (1999) Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22(7):1186–1190
8. Bidasee KR, Nallani K et al (2003a) Chronic diabetes increases advances glycation end products on cardiac ryanodine receptors calcium-release channels (primers). Diabetes 52:1825–1836
9. Bidasee KR, Xu L et al (2003b) Diketopyridylryanodine has three concentration-dependent effects on the cardiac calcium-release channel/ryanodine receptor. J Biol Chem 278(16):14237–14248
10. 2+-ATPase. Diabetes 53(2):463–473
11. Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223–234
12. Bucala R, Tracey KJ et al (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Investig 87(2):432–438
13. Bucciarelli LG, Kaneko M et al (2006) Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113(9):1226–1234
14. Bucciarelli LG, Ananthakrishnan R et al (2008) RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57(7):1941–1951
15. Campbell DJ, Somaratne JB et al (2012) Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels. PLoS One 7(11):e49813
16. Corman B, Duriez M et al (1998) Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci USA 95(3):1301–1306
17. Deluyker D, Ferferieva V et al (2016) Cross-linking versus RAGE: how do high molecular weight advanced glycation products induce cardiac dysfunction? Int J Cardiol 210:100–108
18. Donaldson C, Taatjes DJ et al (2010) Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol 134(1):23–30
19. Esposito C, Gerlach H et al (1989) Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170(4):1387–1407
20. Finot PA, Magnenat E (1981) Metabolic transit of early and advanced Maillard products. Prog Food Nutr Sci 5(1–6):193–207
21. Foerster A, KüHNE Y, Henle T (2005) Studies on absorption and elimination of dietary maillard reaction products. Ann N Y Acad Sci 1043:474–481
22. Furth AJ (1997) Glycated proteins in diabetes. Br J Biomed Sci 54(3):192–200
23. Gerdemann A, Lemke HD et al (2000) Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 54(4):276–283
24. Glomb MA, Monnier VM (1995) Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270(17):10017–10026
25. Goldberg T, Cai W et al (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104(8):1287–1291
26. Goldin A, Beckman JA et al (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114(6):597–605
27. Grzebyk E, Knapik-Kordecka M et al (2013) Advanced glycation end-products and cathepsin cysteine protease in type 2 diabetic patients. Pol Arch Med Wewn 123(7–8):364–370
28. Hartog JW, Voors AA et al (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 9(12):1146–1155
29. He C, Sabol J et al (1999) Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48(6):1308–1315
30. Hegab Z, Gibbons S et al (2012) Role of advanced glycation end products in cardiovascular disease. World J Cardiol 4(4):90–102
31. Heidland A, Sebekova K et al (2004) Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. Heart 90(11):1269–1274
32. Hellwig M, Geissler S et al (2011) Transport of free and peptide-bound glycated amino acids: synthesis, transepithelial flux at Caco-2 cell monolayers, and interaction with apical membrane transport proteins. ChemBioChem 12(8):1270–1279
33. Henle T (2003) AGEs in foods: do they play a role in uremia? Kidney Int 63:S145–S147
34. Jara N, Leal MJ et al (2012) Dietary intake increases serum levels of carboxymethil-lysine (CML) in diabetic patients. Nutr Hosp 27(4):1272–1278
35. Kilhovd BK, Berg TJ et al (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22(9):1543–1548
36. Kisugi R, Kouzuma T et al (2007) Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 382(1–2):59–64
37. Koyama Y, Takeishi Y et al (2007) High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13(3):199–206
38. Kranstuber AL, Del Rio C et al (2012) Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. Front Physiol 3:292
39. Li SY, Sigmon VK et al (2007) Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci 80(11):1051–1056
40. Little WC, Zile MR et al (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11(3):191–195
41. Lorenzi M (2007) The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res 2007:61038
42. Luevano-Contreras C, Chapman-Novakofski K (2010) Dietary advanced glycation end products and aging. Nutrients 2(12):1247–1265
43. Makita Z, Bucala R et al (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343(8912):1519–1522
44. McNair ED, Wells CR et al (2009) Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 18(4):187–192
45. Miura J, Yamagishi S et al (2003) Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complicat 17(1):16–21
46. Moheimani F, Morgan PE et al (2010) (2010) Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function: possible links between diabetes and atherosclerosis. Biochim Biophys Acta 1802(6):561–571
47. Monnier VM, Sun W et al (2014) Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications. Clin Chem Lab Med 52(1):21–32
48. Nagai R, Matsumoto K et al (2000) Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 49(10):1714–1723
49. Nielsen JM, Kristiansen SB et al (2009) Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 11(7):638–647
50. Ott C, Jacobs K et al (2014) Role of advanced glycation end products in cellular signaling. Redox Biol 2:411–429
51. Penfold SA, Coughlan MT et al (2010) Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 78(3):287–295
52. Petrova R, Yamamoto Y et al (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34(10):1425–1431
53. Peyroux J, Sternberg M (2006) Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 54(7):405–419
54. Poulsen MW, Hedegaard RV et al (2013) Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 60:10–37
55. Poulsen MW, Andersen JM et al (2016) Short-term effects of dietary advanced glycation end products in rats. Br J Nutr 115(4):629–636
56. Ramasamy R, Schmidt AM (2012) Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep 9(2):107–116
57. Rojas A, Mercadal E et al (2008) Advanced Glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol 6(1):44–51
58. Schalkwijk CG, Stehouwer CD et al (2004) Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 20(5):369–382
59. Seiquer I, Diaz-Alguacil J et al (2006) Diets rich in Maillard reaction products affect protein digestibility in adolescent males aged 11-14 y. Am J Clin Nutr 83(5):1082–1088
60. Sharp PS, Rainbow S et al (2003) Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 20(7):575–579
61. Singh R, Barden A et al (2001) Advanced glycation end-products: a review. Diabetologia 44(2):129–146
62. Takeuchi M, Makita Z et al (1999) Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 5(6):393–405
63. Takeuchi M, Takino J et al (2015) Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan. PLoS One 10(3):e0118652
64. Tang Y, Chen A (2014) Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Investig 94(5):503–516
65. Thomas MC, Tsalamandris C et al (2004) Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 66(3):1167–1172
66. Thomas MC, Forbes JM et al (2005) Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Ann N Y Acad Sci 1043:644–654
67. Thornalley PJ (1999) Clinical significance of glycation. Clin Lab 45:263–273
68. Thornalley PJ, Langborg A et al (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344(Pt 1):109–116
69. Uribarri J, Woodruff S et al (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110(6):911–916 (e912)
70. Vazzana N, Santilli F et al (2009) Soluble forms of RAGE in internal medicine. Intern Emerg Med 4(5):389–401
71. Vlassara H, Striker GE (2011) AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 7(9):526–539
72. Vlassara H, Striker GE (2013) Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin N Am 42(4):697–719
73. Wang Z, Jiang Y et al (2012) Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 221(2):387–396
74. Wautier JL, Zoukourian C et al (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Investig 97(1):238–243
75. Willemsen S, Hartog JW et al (2012a) Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Fail Rev 17(2):221–228
76. Willemsen S, Hartog JW et al (2012b) The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J 164(5):742–749 (e743)
77. Yan SF, Ramasamy R et al (2009) The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med 11:e9
78. Zieman SJ (2004) Advanced glycation end products cross-linking pathophysiologic role and therapeutic target in cardiovascular disease. Drugs 64(5):459–470